Tempus AI, Inc. (TEM) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Insights data licensing and insights growth (year over year) | 44.10 percent | FY2026-Q1 |
| Minimal Residual Disease tests (volume) | 6.5K | FY2026-Q1 |
| Adjusted earnings before interest, taxes, depreciation and amortization | 12.9M | FY2025-Q4 |
| Net loss per share attributable to common shareholders (non-GAAP) | -0.04 USD_per_share | FY2025-Q4 |
| Hereditary tests volume growth (year over year) | 23.00 percent | FY2025-Q4 |
| Clinical tests volume growth (year over year) | 33.00 percent | FY2025-Q3 |
| Genomics unit growth (year over year) | 22.50 percent | FY2024-Q4 |
Back to TEM overview · TEM earnings · TEM holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.